BACKGROUND: The Banff schema is the internationally accepted standard for grading acute liver-allograft rejection, but it has not been prospectively tested. METHODS: Complete Banff grading was prospectively applied to 2,038 liver-allograft biopsies from 901 adult tacrolimus-treated primary hepatic allograft recipients between August 1995 and September 2001. Histopathologic data was melded with demographic, clinical, and laboratory data into a database on an ongoing basis using locally developed software. RESULTS: Acute rejection developed in 575 of 901 (64%) patients and the worst grade was mild in 422 of 575 (73%). At least one episode of moderate or severe acute rejection developed in 153 of 901 (17%) patients and most episodes, irrespective of severity, occurred within the first year after transplantation. Patients with moderate or severe acute rejection showed higher alanine aminotransferase (P =0.007) and aspartate aminotransferase ( P=0.07) levels and were more likely to develop perivenular fibrosis on follow-up biopsies (P =0.001) and graft failure from acute or chronic rejection ( P=0.004) than those with mild rejection. Regardless of severity, 80% of patients with acute rejection did not develop significant fibrosis in follow-up biopsies, and graft failure from acute or chronic rejection occurred in only 11 of 901 (1%) allografts. CONCLUSIONS: Most acute-rejection episodes are mild and do not lead to clinically significant architectural sequelae. When tested prospectively under real-life and -time conditions, the Banff schema can be used to identify those few patients who are potentially at risk for more significant problems. Creation, capture, and integration of non-free text, or "digital," pathology data can be used to prospectively conduct outcomes-based research in transplantation.
BACKGROUND: The Banff schema is the internationally accepted standard for grading acute liver-allograft rejection, but it has not been prospectively tested. METHODS: Complete Banff grading was prospectively applied to 2,038 liver-allograft biopsies from 901 adult tacrolimus-treated primary hepatic allograft recipients between August 1995 and September 2001. Histopathologic data was melded with demographic, clinical, and laboratory data into a database on an ongoing basis using locally developed software. RESULTS: Acute rejection developed in 575 of 901 (64%) patients and the worst grade was mild in 422 of 575 (73%). At least one episode of moderate or severe acute rejection developed in 153 of 901 (17%) patients and most episodes, irrespective of severity, occurred within the first year after transplantation. Patients with moderate or severe acute rejection showed higher alanine aminotransferase (P =0.007) and aspartate aminotransferase ( P=0.07) levels and were more likely to develop perivenular fibrosis on follow-up biopsies (P =0.001) and graft failure from acute or chronic rejection ( P=0.004) than those with mild rejection. Regardless of severity, 80% of patients with acute rejection did not develop significant fibrosis in follow-up biopsies, and graft failure from acute or chronic rejection occurred in only 11 of 901 (1%) allografts. CONCLUSIONS: Most acute-rejection episodes are mild and do not lead to clinically significant architectural sequelae. When tested prospectively under real-life and -time conditions, the Banff schema can be used to identify those few patients who are potentially at risk for more significant problems. Creation, capture, and integration of non-free text, or "digital," pathology data can be used to prospectively conduct outcomes-based research in transplantation.
Authors: Timothy M Schmitt; Melissa Phillips; Robert G Sawyer; Patrick Northup; Klaus D Hagspiel; Timothy L Pruett; Hugo J R Bonatti Journal: Dig Dis Sci Date: 2010-03-18 Impact factor: 3.199
Authors: Amadeo Marcos; Bijan Eghtesad; John J Fung; Paulo Fontes; Kusum Patel; Michael Devera; Wallis Marsh; Timothy Gayowski; Anthony J Demetris; Edward A Gray; Bridget Flynn; Adriana Zeevi; Noriko Murase; Thomas E Starzl Journal: Transplantation Date: 2004-10-15 Impact factor: 4.939
Authors: A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl Journal: Am J Surg Pathol Date: 2004-05 Impact factor: 6.394
Authors: J G Brain; H Robertson; E Thompson; E H Humphreys; A Gardner; T A Booth; D E J Jones; S C Afford; T von Zglinicki; A D Burt; J A Kirby Journal: Am J Transplant Date: 2013-06-10 Impact factor: 8.086
Authors: Jae Geun Lee; Juhan Lee; Jung Jun Lee; Seung Hwan Song; Man Ki Ju; Gi Hong Choi; Myoung Soo Kim; Jin Sub Choi; Soon Il Kim; Dong Jin Joo Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889
Authors: Angus Hann; Daniel-Clement Osei-Bordom; Desley A H Neil; Vincenzo Ronca; Suz Warner; M Thamara P R Perera Journal: Front Immunol Date: 2020-06-22 Impact factor: 7.561